非酒精性脂肪性肝病非药物管理的证据总结

doi:10.3761/j.issn.1672-9234.2025.09.017

摘要/Abstract

摘要：

目的总结非酒精性脂肪性肝病非药物管理的最佳证据。方法检索决策支持系统、中英文数据库、指南网站及专业学会网站中有关非酒精性脂肪性肝病非药物管理的文献，检索时限为建库至2025年5月1日。由2名经过循证护理培训的研究者独立筛选文献、提取资料并对文献的方法学质量进行评价后，对证据进行提取、汇总及等级评定。结果共纳入24篇文献，其中指南11篇、专家共识8篇、系统评价5篇，从支持与随访管理、体重管理、饮食管理、运动管理4个方面总结出34条最佳证据。结论总结的非酒精性脂肪性肝病非药物管理的最佳证据可为医护人员开展患者个体化健康管理指导提供依据。

关键词: 非酒精性脂肪性肝病, 非药物管理, 证据总结, 循证护理

Abstract:

Objective To summarize the best evidence for non-pharmacological management of patients with non-alcoholic fatty liver disease（NAFLD）. Methods A systematic search was conducted across decision support systems，Chinese and English databases，guideline websites，and professional society websites for literature on non-pharmacological management of NAFLD from inception to May 1，2025. After independent literature screening，data extraction，and methodological quality assessment by two researchers trained in evidence-based nursing，the evidence was extracted，graded，and synthesized. Results A total of 24 literature were included，comprising 11 guidelines，eight expert consensus statements，and five systematic reviews. These yielded 34 best evidence items categorized into four domains：support and follow-up management，weight management，dietary management，and exercise management. Conclusion This study consolidates the best evidence for non-pharmacological management of NAFLD，which can offer an evidence-based foundation for delivering individualized lifestyle guidance to patients.

Key words: Non-alcoholic fatty liver disease, Non-pharmacological management, Evidence summary, Evidence-based nursing

盛贵箫, 桑明, 梅彬彬, 杨丽萍. 非酒精性脂肪性肝病非药物管理的证据总结[J]. 中华护理教育, 2025, 22(9): 1133-1140.

SHENG Guixiao, SANG Ming, MEI Binbin, YANG Liping. Evidence summary for non-pharmacological management of non-alcoholic fatty liver disease[J]. Chinese Journal of Nursing Education, 2025, 22(9): 1133-1140.

图/表 4

参考文献 46

[1]	Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5):1797-1835. doi: 10.1097/HEP.0000000000000323 pmid: 36727674
[2]	Lee HW, Wong VW. Changing NAFLD epidemiology in China[J]. Hepatology, 2019, 70(4):1095-1098. doi: 10.1002/hep.30848 pmid: 31298746
[3]	Wong VW, Ekstedt M, Wong GL, et al. Changing epidemiology,global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79(3):842-852.
[4]	Avery L, Exley C, McPherson S, et al. Lifestyle behavior change in patients with nonalcoholic fatty liver disease:a qualitative study of clinical practice[J]. Clin Gastroenterol Hepatol, 2017, 15(12):1968-1971.
[5]	周芬, 郝玉芳, 丛雪, 等. 指南研究与评价工具AGREE Ⅱ及各领域分值的补充解释及思考[J]. 护理学报, 2018, 25(18):56-58.
[6]	周英凤, 顾莺, 胡雁, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具——干预性研究的质量评价(一)[J]. 护士进修杂志, 2018, 33(1):24-26.
[7]	顾莺, 张慧文, 周英凤, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具:系统评价的方法学质量评价[J]. 护士进修杂志, 2018, 33(8):701-703.
[8]	European Association for the Study of the Liver(EASL),European Association for the Study of Diabetes(EASD), Eu-ropean Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81(3):492-542.
[9]	Eslam M, Fan JG, Yu ML, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2025, 19(2):261-301.
[10]	中国老年学和老年医学学会. 老年非酒精性脂肪性肝病慢病管理指南[J]. 中西医结合肝病杂志, 2022, 32(8):769-772.
[11]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5):418-434.
[12]	中国医药生物技术协会慢病管理分会, 中国研究型医院学会肝病(中西医结合)专业委员会, 中华医学会全科医学分会, 等. 代谢相关脂肪性肝病基层诊疗与管理指南(2025年)[J]. 中华全科医师杂志, 2025, 24(5):513-525.
[13]	Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice gui-delines:management of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2021, 27(3):363-401.
[14]	Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nona-lcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56(11):951-963.
[15]	Cusi K, Isaacs S, Barb D, et al. American Association of Clini-cal Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings:co-sponsored by the American Association for the Study of Liver Diseases(AASLD)[J]. Endocr Pract, 2022, 28(5):528-562.
[16]	Italian Association for the Study of the Liver(AISF),the Italian Society of Diabetology(SID),the Italian Society of Obe-sity(SIO). Non-alcoholic fatty liver disease in adults 2021:a clinical practice guideline of the Italian Association for the Study of the Liver(AISF),the Italian Society of Diabetology(SID) and the Italian Society of Obesity(SIO)[J]. Dig Liver Dis, 2022, 54(2):170-182.
[17]	Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline:clinical nutrition in liver disease[J]. Clin Nutr, 2020, 39(12):3533-3562. doi: 10.1016/j.clnu.2020.09.001 pmid: 33213977
[18]	Arab JP, Dirchwolf M, álvares-da-Silva MR, et al. Latin American Association for the Study of the Liver(ALEH) practice guida-nce for the diagnosis and treatment of non-alcoholic fatty liver disease[J]. Ann Hepatol, 2020, 19(6):674-690.
[19]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 中国脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 中华肝脏病杂志, 2019, 27(10):748-753.
[20]	McPherson S, Armstrong MJ, Cobbold JF, et al. Quality stan-dards for the management of non-alcoholic fatty liver disease(NAFLD):consensus recommendations from the British Asso-ciation for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group[J]. Lancet Gastroenterol Hepatol, 2022, 7(8):755-769.
[21]	Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplanta-tion[J]. Transplantation, 2019, 103(1):57-67.
[22]	中华医学会内分泌学分会, 中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J]. 中华内分泌代谢杂志, 2021, 37(7):589-598.
[23]	Long MT, Noureddin M, Lim JK. AGA clinical practice upda-te:diagnosis and management of nonalcoholic fatty liver disease in lean individuals:expert review[J]. Gastroenterology, 2022, 163(3):764-774.e1.
[24]	Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease:expert review[J]. Gastroenterology, 2021, 160(3):912-918. doi: 10.1053/j.gastro.2020.11.051 pmid: 33307021
[25]	Ratziu V, Ghabril M, Romero-Gomez M, et al. Recommenda-tions for management and treatment of nonalcoholic steatohe-patitis[J]. Transplantation, 2019, 103(1):28-38. doi: 10.1097/TP.0000000000002483 pmid: 30300289
[26]	Zheng JL, Zhao LG, Dong JW, et al. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression:a systematic review[J]. Clin Nutr, 2022, 41(10):2295-2307.
[27]	Dai W, Liu HY, Zhang TJ, et al. Dairy product consumption was associated with a lower likelihood of non-alcoholic fatty liver disease:a systematic review and meta-analysis[J]. Front Nutr, 2023,10:1119118.
[28]	Sabag A, Barr L, Armour M, et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat:a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(3):862-881.
[29]	Lange M, Nadkarni D, Martin L, et al. Intermittent fasting im-proves hepatic end points in nonalcoholic fatty liver disease:a systematic review and meta-analysis[J]. Hepatol Commun, 2023, 7(8):e0212.
[30]	Zafar Y, Sohail MU, Saad M, et al. eHealth interventions and patients with metabolic dysfunction-associated steatotic liver disease:a systematic review and meta-analysis[J]. BMJ Open Gastroenterol, 2025, 12(1):e001670.
[31]	Younossi Z, Aggarwal P, Shrestha I, et al. The burden of non-alcoholic steatohepatitis:a systematic review of health-related quality of life and patient-reported outcomes[J]. JHEP Rep, 2022, 4(9):100525.
[32]	Stewart KE, Haller DL, Sargeant C, et al. Readiness for beha-viour change in non-alcoholic fatty liver disease:implications for multidisciplinary care models[J]. Liver Int, 2015, 35(3):936-943. doi: 10.1111/liv.12483 pmid: 24521540
[33]	Kotronoulas G, Papadopoulou C, Simpson MF, et al. Using pa-tient-reported outcome measures to deliver enhanced suppor-tive care to people with lung cancer:feasibility and accepta-bility of a nurse-led consultation model[J]. Support Care Can-cer, 2018, 26(11):3729-3737.
[34]	Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects[J]. J Hepatol, 1991, 12(2):224-229. pmid: 2051001
[35]	Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces fea-tures of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2):367-378.e5;quize14-5. doi: 10.1053/j.gastro.2015.04.005 pmid: 25865049
[36]	邵洁. 基于自我效能理论的护理干预对超重/肥胖不孕患者体质量管理的效果研究[D]. 兰州: 兰州大学, 2021.
[37]	Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults:systematic review and meta-analysis[J]. Hepatol Commun, 2020, 4(7):953-972.
[38]	Fernández-Mincone T, Contreras-Briceño F, Espinosa-Ramírez M, et al. Nonalcoholic fatty liver disease and sarcopenia:patho-physiological connections and therapeutic implications[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(12):1141-1157.
[39]	Matsuoka L, Chotai PN, Slaughter J, et al. A single-center study of nonalcoholic fatty liver disease and nonalcoholic steatohe-patitis recurrence in recipients of liver transplant for treat-ment of nonalcoholic steatohepatitis cirrhosis[J]. Exp Clin Transplant, 2022, 20(2):150-156. doi: 10.6002/ect.2021.0343 pmid: 35037605
[40]	Losurdo G, Castellaneta A, Rendina M, et al. Systematic review with meta-analysis:de novo non-alcoholic fatty liver disease in liver-transplanted patients[J]. Aliment Pharmacol Ther, 2018, 47(6):704-714.
[41]	Richards J, Gunson B, Johnson J, et al. Weight gain and obe-sity after liver transplantation[J]. Transpl Int, 2005, 18(4):461-466. doi: 10.1111/j.1432-2277.2004.00067.x pmid: 15773968
[42]	Yaskolka Meir A, Rinott E, Tsaban G, et al. Effect of green-Mediterranean diet on intrahepatic fat:the DIRECT PLUS randomised controlled trial[J]. Gut, 2021, 70(11):2085-2095. doi: 10.1136/gutjnl-2020-323106 pmid: 33461965
[43]	Ivancovsky-Wajcman D, Zelber-Sagi S, Fliss Isakov N, et al. Serum soluble receptor for AGE(sRAGE) levels are associa-ted with unhealthy lifestyle and nonalcoholic fatty liver disease[J]. Clin Transl Gastroenterol, 2019, 10(5):1-10.
[44]	Ryu S, Chang Y, Jung HS, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease[J]. J Hepatol, 2015, 63(5):1229-1237. doi: 10.1016/j.jhep.2015.07.010 pmid: 26385766
[45]	Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resista-nce exercise in non-alcoholic fatty liver disease:a systematic review[J]. J Hepatol, 2017, 66(1):142-152. doi: S0168-8278(16)30488-3 pmid: 27639843
[46]	Younossi ZM, Zelber-Sagi S, Henry L, et al. Lifestyle interven-tions in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(11):708-722. doi: 10.1038/s41575-023-00800-4 pmid: 37402873